Functional gene-expression analysis shows involvement of schizophrenia-relevant pathways in patients with 22q11 deletion syndrome

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  van Beveren, Nico J M ^a,d   Krab, Lianne C ^a   Swagemakers, Sigrid ^a   Buitendijk, Gabriella ^a   Boot, Erik ^f   van der Spek, Peter ^a   Elgersma, Ype ^a   van Amelsvoort, Therese A M J ^b,c,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Mondriaan Mental Health Services   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Delta Center for Mental Health Care   (Netherlands)

^e Virenze Mental Health Care ^*  (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEU DIFFERENTIATION FACTOR; NEUROTROPHIN;

ADOLESCENT; ADULT; ARTICLE; CELL DEATH; CELL STRUCTURE; CHROMOSOME DELETION 22Q11; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN VERSUS NONHUMAN DATA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; CASE CONTROL STUDY; CHROMOSOME 22; CHROMOSOME DELETION; GENE EXPRESSION PROFILING; GENETICS; MOUSE;

ADOLESCENT; ADULT; ANIMALS; CASE-CONTROL STUDIES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84858716319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033473     Document Type: Article

References (46)

1. Murphy KC, Jones LA, Owen MJ, (1999) High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56 (10): 940-5.
2. van Amelsvoort T, Daly E, Henry J, Robertson D, Ng V, et al. (2004) Brain anatomy in adults with velocardiofacial syndrome with and without schizophrenia: preliminary results of a structural magnetic resonance imaging study. Arch Gen Psychiatry 61: 1085-1096.
3. Meechan DW, Maynard TM, Gopalakrishna D, Wu Y, LaMantia AS, (2007) When half is not enough: gene expression and dosage in the 22q11 deletion syndrome. Gene Expr 13: 299-310.
4. Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, et al. (2003) A comprehensive analysis of 22q11 gene expression in the developing and adult brain. Proc Natl Acad Sci U S A 100: 14433-14438.
5. Williams NM, Glaser B, Norton N, Williams H, Pierce T, et al. (2008) Strong evidence that GNB1L is associated with schizophrenia. Hum Mol Genet 17: 555-566.
6. Konradi C, (2005) Gene expression microarray studies in polygenic psychiatric disorders: applications and data analysis. Brain Res Brain Res Rev 50: 142-155.
7. Mirnics K, Levitt P, Lewis DA, (2006) Critical appraisal of DNA microarrays in psychiatric genomics. Biol Psychiatry 60: 163-176.
8. Sullivan PF, Fan C, Perou CM, (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141: 261-268.
9. Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, et al. (2004) Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 67: 4-52.
10. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, et al. (2006) Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82: 175-183.
11. Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, et al. (2005) Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am J Med Genet B Neuropsychiatr Genet 136: 12-25.
12. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, et al. (2005) Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci U S A 102: 15533-15538.
13. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, et al. (2005) Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 133: 1-5.
14. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
15. Callegaro A, Basso D, Bicciato S, (2006) A locally adaptive statistical procedure (LAP) to identify differentially expressed chromosomal regions. Bioinformatics 22: 2658-2666.
16. Kasamatsu A, Endo Y, Uzawa K, Nakashima D, Koike H, et al. (2005) Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses Int J Biochem Cell Biol 37: 1869-1880.
17. Sivagnanasundaram S, Fletcher D, Hubank M, Illingworth E, Skuse D, et al. (2007) Differential gene expression in the hippocampus of the Df1/+ mice: a model for 22q11.2 deletion syndrome and schizophrenia. Brain Res 1139: 48-59.
18. Meechan DW, Maynard TM, Wu Y, Gopalakrishna D, Lieberman JA, et al. (2006) Gene dosage in the developing and adult brain in a mouse model of 22q11 deletion syndrome. Mol Cell Neurosci 33: 412-428.
19. McDonald-McGinn DM, Sullivan KE, (2011) Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore) 90 (1): 1-18.
20. Jawad AF, Donald-McGinn DM, Zackai E, Sullivan KE, (2001) Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 139: 715-723.
21. Kanaya Y, Ohga S, Ikeda K, Furuno K, Ohno T, et al. (2006) Maturational alterations of peripheral T cell subsets and cytokine gene expression in 22q11.2 deletion syndrome. Clin Exp Immunol 144: 85-93.
22. Kornfeld SJ, Zeffren B, Christodoulou CS, Day NK, Cawkwell G, et al. (2000) DiGeorge anomaly: a comparative study of the clinical and immunologic characteristics of patients positive and negative by fluorescence in situ hybridization. J Allergy Clin Immunol 105: 983-987.
23. Gennery AR, (2012) Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci 69 (1): 17-27.
24. Yovel G, Sirota P, Mazeh D, Shakhar G, Rosenne E, et al. (2000) Higher natural killer cell activity in schizophrenic patients: the impact of serum factors medication, and smoking. Brain Behav Immun 14: 153-169.
25. Kobrynski LJ, Sullivan KE, (2007) Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes. Lancet 370: 1443-1452.
26. Shoval G, Weizman A, (2005) The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15: 319-329.
27. Van Beveren NJM, Van der Spelt JJ, De Haan L, Fekkes D, (2006) Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol 16: 469-480.
28. Carter CJ, (2006) Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr Res 86: 1-14.
29. Straub RE, Weinberger DR, (2006) Schizophrenia genes-famine to feast. Biol Psychiatry 60: 81-83.
30. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT, (2006) Neurobiology of schizophrenia. Neuron 52: 139-153.
31. Barnes A, Isohanni M, Barnett JH, Pietiläinen O, Veijola J, et al. (2012) Neuregulin-1 genotype is associated with structural differences in the normal human brain. Neuroimage 1;59 (3): 2057-61.
32. van Amelsvoort T, Daly E, Robertson D, Suckling J, Ng V, et al. (2001) Structural brain abnormalities associated with deletion at chromosome 22q11: quantitative neuroimaging study of adults with velo-cardio-facial syndrome. Br J Psychiatry 178: 412-9.
33. Baker K, Chaddock CA, Baldeweg T, Skuse D, (2011) Neuroanatomy in adolescents and young adults with 22q11 deletion syndrome: comparison to an IQ-matched group. Neuroimage 15;55 (2): 491-9.
34. da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, et al. (2011) White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. Schizophr Res 132 (1): 75-83.
35. Duijff SN, Klaassen PWJ, Swanenburg de Veye HFN, Beemer FA, Sinnema G, et al. (2012) Cognitive development in children with 22q11.2 deletion syndrome. Br J Psychiatry in press.
36. Aggarwal VS, Liao J, Bondarev A, Schimmang T, Lewandoski M, et al. (2006) Dissection of Tbx1 and Fgf interactions in mouse models of 22q11DS suggests functional redundancy. Hum Mol Genet 1;15 (21): 3219-28.
37. Guo T, McDonald-McGinn D, Blonska A, Shanske A, Bassett AS, et al. (2011) Genotype and cardiovascular phenotype correlations with TBX1 in 1,022 velo-cardio-facial/DiGeorge/22q11.2 deletion syndrome patients. Hum Mutat 32 (11): 1278-89.
38. Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, et al. (2001) Tbx1haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 1;410 (6824): 97-101.
39. Merscher S, Funke B, Epstein JA, Heyer J, Puech A, et al. (2001) TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell 23;104 (4): 619-29.
40. Jerome LA, Papaioannou VE, (2001) DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat Genet 27 (3): 286-91.
41. Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, et al. (2003) Role of TBX1 in human del22q11.2 syndrome. Lancet 25;362 (9393): 1366-73.
42. Klejbor I, Myers JM, Hausknecht K, Corso TD, Gambino AS, et al. (2006) Fibroblast growth factor receptor signaling affects development and function of dopamine neurons-inhibition results in a schizophrenia-like syndrome in transgenic mice. J Neurochem 97: 1243-1258.
43. Hashimoto K, Shimizu E, Komatsu N, Nakazato M, Okamura N, et al. (2003) Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatry Res 120: 211-218.
44. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, et al. (2007) 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6: 141-149.
45. Gladkevich A, Kauffman HF, Korf J, (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28: 559-576.
46. Insel TR, Rethinking schizophrenia (2010) Nature 11;468 (7321): 187-93.